Fig. 1

Incidence rates/1000 patient-years (95% CI) for A infections requiring hospitalization and B overall malignancy. For GISEA, IRs were calculated using the mean duration of therapy (in months) and adverse event counts for infections requiring hospitalization and overall malignancies; for overall malignancy, the calculated IR used first- and second-line abatacept adverse event counts from November 2015. No CIs were provided by the ORA or GISEA registries for any of the IRs. For SCQM, IRs are by exposure group with mid-imputed dates of occurrence. ATTRA, Anti-TNF Therapy in Rheumatoid Arthritis; BIOBADASER, Spanish Register of Adverse Events of Biological Therapies in Rheumatic Diseases; DANBIO, Danish Rheumatologic Database; CI, confidence interval; GISEA, Italian Group for the Study of Early Arthritis; IR, incidence rate; ORA, Orencia and Rheumatoid Arthritis; p-y, patient-years; ROB-FIN, National Registry of Antirheumatic and Biological Treatment in Finland; SCQM, Swiss Clinical Quality Management